Quince Therapeutics, Inc.(QNCX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

QNCX Quince Therapeutics, Inc.

Not Yet Opened 01-23 16:00:00 EST

3.08

-0.16

-4.94%

盘后3.07

-0.01-0.32%

19:35 EST

High3.23	Low3.00	Vol1.15M
Open3.22	D1 Closing3.24	Amplitude6.94%
Mkt Cap171.50M	Tradable Cap152.64M	Total Shares55.68M
T/O3.53M	T/O Rate2.33%	Tradable Shares49.56M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"QNCX","market":"US","secType":"STK","nameCN":"Quince Therapeutics, Inc.","latestPrice":3.08,"timestamp":1769202000000,"preClose":3.24,"halted":0,"volume":1153222,"hourTrading":{"tag":"盘后","latestPrice":3.07,"preClose":3.08,"latestTime":"19:35 EST","volume":9950,"amount":30545.4135,"timestamp":1769214930495,"change":-0.01,"changeRate":-0.003247,"amplitude":0.012987},"delay":0,"changeRate":-0.049382716049382755,"floatShares":49558000,"shares":55681490,"eps":-1.209231,"marketStatus":"Not Yet Opened","change":-0.16,"latestTime":"01-23 16:00:00 EST","open":3.22,"high":3.225,"low":3,"amount":3530897.0632740003,"amplitude":0.069444,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.209231,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1769418000000},"marketStatusCode":0,"adr":0,"listingDate":1557374400000,"exchange":"NASDAQ","adjPreClose":3.24,"preHourTrading":{"tag":"盘前","latestPrice":3.25,"preClose":3.24,"latestTime":"09:29 EST","volume":5185,"amount":16888.45756,"timestamp":1769178558082,"change":0.01,"changeRate":0.003086,"amplitude":0.083302},"postHourTrading":{"tag":"盘后","latestPrice":3.07,"preClose":3.08,"latestTime":"19:35 EST","volume":9950,"amount":30545.4135,"timestamp":1769214930495,"change":-0.01,"changeRate":-0.003247,"amplitude":0.012987},"volumeRatio":0.8162401800900032,"impliedVol":3.987,"impliedVolPercentile":0.992},"requestUrl":"/m/hq/s/QNCX/tweets","defaultTab":"tweets","newsList":[{"id":"2605142978","title":"Nasdaq Net Change Percentage Gainers & Losers","url":"https://stock-news.laohu8.com/highlight/detail?id=2605142978","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605142978?lang=en_us&edition=fundamental","pubTime":"2026-01-21 06:30","pubTimestamp":1768948200,"startTime":"0","endTime":"0","summary":"Leverage 2X Lg IREN Dly     IREG     36.04     6.52     22.08        68,173. Defiance Dly Target 2X Lg   SMCX     13.76     2.47     21.88     6,989,430. GrShr 2x Long SMCI Daily    SMCL      5.46     0.97     21.60    14,233,848. Aimei Health Technology     AFJK     55.23     9.22     20.04       128,874. Airship AI Holdings         AISP      4.32     0.72     20.00     4,387,847. Defiance Lvg Lg+Incm SMCI   SMCC      6.98     0.94     15.53        84,793. Direxion Dly MU Bull 2X      MUU    157.33    21.04     15.44     2,306,047. Defiance Tgt 2X Shrt SMCI   SMCZ     42.75   -12.42    -22.51       638,309. Defiance Tgt 2X Lg DKNG     DKNX      8.37    -1.59    -15.95       265,114. Evolution Metals & Techs    EMAT      8.40    -1.52    -15.32       104,991. Defiance Tgt 2X Lg VST      VSTL     12.81    -2.30    -15.22       984,232. Defiance Tgt 2x Shrt IONQ   IONZ     16.27    -2.66    -14.05     3,905,099. Leverage 2x Lg FIG Dly      FIGG      2.80    -0.42    -13.04     1,155,398.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RKLZ","BK4585","DKNX","FIGG","BK4543","LU1861220033.SGD","IONZ","IREG","ABUS","CTMX","AISP","PRLD","SMCX","DKNG","LU1861215975.USD","QNCX","IBRX","BK4170","SMCZ","AXTI","BK4588","LU0053671581.USD","VSTL","SMCC","SMCL","EMAT","AFJK"],"gpt_icon":1},{"id":"2595075514","title":"Quince Therapeutics Director Luca Benatti Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2595075514","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595075514?lang=en_us&edition=fundamental","pubTime":"2025-12-30 06:36","pubTimestamp":1767047808,"startTime":"0","endTime":"0","summary":"Luca Benatti, Director of Quince Therapeutics Inc., reported a disposal of common shares of Quince Therapeutics Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quince Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 29, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251229:nNDL7rTHJ4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Quince Therapeutics Director Luca Benatti Reports Sale of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","QNCX"],"gpt_icon":0},{"id":"2591475266","title":"BRIEF-Quince Marks Final Patient Visit in NEAT Phase 3 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2591475266","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591475266?lang=en_us&edition=fundamental","pubTime":"2025-12-15 22:53","pubTimestamp":1765810389,"startTime":"0","endTime":"0","summary":"BRIEF-Quince Marks Final Patient Visit in NEAT Phase 3 StudyDec 15 (Reuters) - Quince Therapeutics Inc QNCX.O:QUINCE THERAPEUTICS ANNOUNCES LAST PATIENT LAST VISIT IN PHASE 3 NEAT CLINICAL TRIAL IN PA","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nTUA9SHPZW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNCX","BK4139"],"gpt_icon":0},{"id":"2591961649","title":"Quince Therapeutics Completes Phase 3 NEAT Trial for Ataxia-Telangiectasia Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2591961649","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591961649?lang=en_us&edition=fundamental","pubTime":"2025-12-15 21:01","pubTimestamp":1765803698,"startTime":"0","endTime":"0","summary":"Quince Therapeutics Inc. has announced the completion of patient visits in its pivotal Phase 3 NEAT clinical trial evaluating encapsulated dexamethasone sodium phosphate  for the treatment of Ataxia-Telangiectasia (A-T), a rare pediatric neurodegenerative disease with no currently approved treatments. The international, multicenter, randomized, double-blind, placebo-controlled study enrolled 105 participants and was conducted under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration. The primary efficacy endpoint is based on changes in the Rescored modified International Cooperative Ataxia Rating Scale  from baseline to the last efficacy visit. Quince Therapeutics expects to report topline results from the trial in the middle of the first quarter of 2026. Results have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nNDL5dGqVG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNCX","BK4139"],"gpt_icon":0},{"id":"2591668649","title":"Quince Therapeutics Announces Last Patient Last Visit in Phase 3 Neat Clinical Trial in Patients With Ataxia-Telangiectasia","url":"https://stock-news.laohu8.com/highlight/detail?id=2591668649","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591668649?lang=en_us&edition=fundamental","pubTime":"2025-12-15 21:00","pubTimestamp":1765803604,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nTUA9SHPZW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","QNCX"],"gpt_icon":0},{"id":"2591649659","title":"Quince Therapeutics - Expects Topline Results in Q1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2591649659","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591649659?lang=en_us&edition=fundamental","pubTime":"2025-12-15 21:00","pubTimestamp":1765803604,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nTUA9SHPZW:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["QNCX","BK4139"],"gpt_icon":0},{"id":"2590558100","title":"Quince Therapeutics Reports Positive Early Clinical Results for eDSP in Pulmonary and Inflammatory Bowel Disorders","url":"https://stock-news.laohu8.com/highlight/detail?id=2590558100","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590558100?lang=en_us&edition=fundamental","pubTime":"2025-12-11 05:05","pubTimestamp":1765400725,"startTime":"0","endTime":"0","summary":"Quince Therapeutics Inc. announced the publication of early-stage clinical studies evaluating its lead asset, eDSP , in pulmonary and inflammatory bowel disorders. The studies, summarized in the journal Frontiers in Drug Delivery, included patients with chronic obstructive pulmonary disease, cystic fibrosis, Crohn's disease, and ulcerative colitis. Results indicated that eDSP was associated with improved clinical outcomes, such as increased FEV1, reduced infections, and corticosteroid withdrawal, without typical corticosteroid-related toxicities. The company stated that topline results from the ongoing Phase 3 NEAT study of eDSP in Ataxia-Telangiectasia are expected in the middle of the first quarter of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investme","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nNDL8zNvhy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNCX","BK4139"],"gpt_icon":0},{"id":"2585517462","title":"Quince Therapeutics to Present at Piper Sandler Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2585517462","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585517462?lang=en_us&edition=fundamental","pubTime":"2025-11-24 21:00","pubTimestamp":1763989241,"startTime":"0","endTime":"0","summary":"Quince Therapeutics Inc. will participate in several investor events in December 2025. On December 3, 2025, CEO and Chief Medical Officer Dirk Thye, M.D., will join a fireside chat at the Piper Sandler 37th Annual Healthcare Conference. On December 11, 2025, President Charles Ryan, J.D., Ph.D., will take part in a panel at the Oppenheimer Movers in Rare Disease Summit. Additionally, on December 16, 2025, Dirk Thye and Chief Operating Officer Brendan Hannah will participate in a virtual Lunch with LifeSci fireside chat hosted by LifeSci Advisors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quince Therapeutics Inc. published the original content used to generate this news brief via Business Wire  on November 24, 2025, and is solely re","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDL1yrX0n:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","QNCX"],"gpt_icon":0},{"id":"2583501876","title":"Oppenheimer Sticks to Its Buy Rating for Quince Therapeutics (QNCX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2583501876","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583501876?lang=en_us&edition=fundamental","pubTime":"2025-11-14 21:37","pubTimestamp":1763127446,"startTime":"0","endTime":"0","summary":"In a report released today, Leland Gershell from Oppenheimer maintained a Buy rating on Quince Therapeutics, with a price target of $10.00. Accordi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/oppenheimer-sticks-to-its-buy-rating-for-quince-therapeutics-qncx-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/oppenheimer-sticks-to-its-buy-rating-for-quince-therapeutics-qncx-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OPY","QNCX"],"gpt_icon":0},{"id":"2582885993","title":"Quince Therapeutics announces positive iDSMB review for eDSP in Phase 3 study","url":"https://stock-news.laohu8.com/highlight/detail?id=2582885993","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582885993?lang=en_us&edition=fundamental","pubTime":"2025-11-11 05:16","pubTimestamp":1762809405,"startTime":"0","endTime":"0","summary":"Quince Therapeutics (QNCX) “announced the positive outcome of its pre-planned safety analysis conducted by an independent data and safety monitorin...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/quince-therapeutics-announces-positive-idsmb-review-for-edsp-in-phase-3-study-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/quince-therapeutics-announces-positive-idsmb-review-for-edsp-in-phase-3-study-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4539","QNCX","BK4007","BK4139"],"gpt_icon":0},{"id":"2582800808","title":"Quince Therapeutics Reports Positive Safety Review for Phase 3 NEAT Trial in Ataxia-Telangiectasia","url":"https://stock-news.laohu8.com/highlight/detail?id=2582800808","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582800808?lang=en_us&edition=fundamental","pubTime":"2025-11-11 05:06","pubTimestamp":1762808772,"startTime":"0","endTime":"0","summary":"Quince Therapeutics Inc. announced a positive outcome from a pre-planned safety analysis conducted by an independent data and safety monitoring board  for its ongoing pivotal Phase 3 NEAT clinical trial. The study is evaluating encapsulated dexamethasone sodium phosphate  in patients with Ataxia-Telangiectasia (A-T). The iDSMB identified no safety concerns and recommended that the trial continue without modifications. The Phase 3 NEAT study is a randomized, double-blind, placebo-controlled trial assessing the neurological effects of eDSP. Topline results from the study are expected to be reported in the first quarter of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quince Therapeutics Inc. published the original content used to ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDLb8JL0x:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNCX","BK4139"],"gpt_icon":0},{"id":"2582338329","title":"Quince Therapeutics - No Safety Concerns Identified, Study to Continue Unmodified","url":"https://stock-news.laohu8.com/highlight/detail?id=2582338329","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582338329?lang=en_us&edition=fundamental","pubTime":"2025-11-11 05:05","pubTimestamp":1762808700,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nTUA1LWDNC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["QNCX","BK4139"],"gpt_icon":0},{"id":"2582298383","title":"Quince Therapeutics - Topline Results From Study Expected in Q1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2582298383","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582298383?lang=en_us&edition=fundamental","pubTime":"2025-11-11 05:05","pubTimestamp":1762808700,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nTUA1LWDNC:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","QNCX"],"gpt_icon":0},{"id":"2581886120","title":"Quince Therapeutics Inc  expected to post a loss of 22 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2581886120","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581886120?lang=en_us&edition=fundamental","pubTime":"2025-11-07 22:10","pubTimestamp":1762524605,"startTime":"0","endTime":"0","summary":"Quince Therapeutics Inc  expected to post a loss of22cents a share - Earnings Preview Quince Therapeutics Inc QNCX.OQ QNCX.O is expected to  show no change in quarterly revenue when it reports  result","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nL8N3WJ1U3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNCX","BK4139"],"gpt_icon":0},{"id":"2576069169","title":"Quince Therapeutics Retracts Statement on NALL Study Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2576069169","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576069169?lang=en_us&edition=fundamental","pubTime":"2025-10-18 04:11","pubTimestamp":1760731896,"startTime":"0","endTime":"0","summary":"Quince Therapeutics Inc. recently addressed investor communications regarding the efficacy of N-acetyl-L-leucine  in treating ataxia-telangiectasia. During a Virtual Investor Day, a company presentation stated that a Phase 2 study of NALL in this condition had failed across all endpoints. This statement was later removed from public materials, with the company advising investors not to rely on it. Quince clarified that the statement was based on a peer-reviewed article in the European Journal of Paediatric Neurology, which reported no significant improvements in ataxia symptoms or motor function, despite some symptom relief, but was not related to the specific Phase 2 study referenced in the presentation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251017:nNDL6gwdCv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","QNCX"],"gpt_icon":0},{"id":"2574419928","title":"Quince Therapeutics Announces Data from Phase 3 Trial on Walking Capacity in Children with AtaxiaTelangiectasia","url":"https://stock-news.laohu8.com/highlight/detail?id=2574419928","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574419928?lang=en_us&edition=fundamental","pubTime":"2025-10-10 04:06","pubTimestamp":1760040369,"startTime":"0","endTime":"0","summary":"Quince Therapeutics Inc. announced the presentation of new data on patient-reported walking capacity in children with Ataxia-Telangiectasia (A-T) at the 54th Child Neurology Society Annual Meeting. The analysis described age-related loss of walking capacity in 372 children with A-T and compared a patient-reported walking scale to clinician-rated measures, including the International Cooperative Ataxia Rating Scale  and the Rescored modified ICARS . The results indicated that all three scales similarly tracked loss of ambulation with age, supporting the use of RmICARS walking capacity components for assessing disease progression in A-T. The findings have been published in the Annals of the Child Neurology Society.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, inve","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251009:nNDL42jPCp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","QNCX"],"gpt_icon":0},{"id":"2573924962","title":"Is Quince Therapeutics (NASDAQ:QNCX) Using Too Much Debt?","url":"https://stock-news.laohu8.com/highlight/detail?id=2573924962","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573924962?lang=en_us&edition=fundamental","pubTime":"2025-10-07 18:41","pubTimestamp":1759833676,"startTime":"0","endTime":"0","summary":"Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qncx/quince-therapeutics/news/is-quince-therapeutics-nasdaqqncx-using-too-much-debt","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qncx/quince-therapeutics/news/is-quince-therapeutics-nasdaqqncx-using-too-much-debt","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["QLD","USJW.SI","QNCX","PSQ","USAW.SI","MNQmain","TQQQ","SQQQ","TSYW.SI","NVIW.SI",".IXIC","QID","NQmain","BK4139","EBIT"],"gpt_icon":1},{"id":"2570383763","title":"Quince Therapeutics Secures Amendment to EIB Credit Facility, Reducing Cash Reserve Requirements and Adjusting Interest Terms for Early 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2570383763","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570383763?lang=en_us&edition=fundamental","pubTime":"2025-09-27 04:45","pubTimestamp":1758919557,"startTime":"0","endTime":"0","summary":"Quince Therapeutics Secures Amendment to EIB Credit Facility, Reducing Cash Reserve Requirements and Adjusting Interest Terms for Early 2026. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quince Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 26, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250926:nNDL3H9kTj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNCX","BK4139"],"gpt_icon":0},{"id":"2570046276","title":"Quince Therapeutics Publishes Positive Phase 3 Data on eDSP for Ataxia-Telangiectasia, Highlighting Sustained Drug Release and Favorable Safety Profile","url":"https://stock-news.laohu8.com/highlight/detail?id=2570046276","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570046276?lang=en_us&edition=fundamental","pubTime":"2025-09-26 04:05","pubTimestamp":1758830759,"startTime":"0","endTime":"0","summary":"Quince Therapeutics Publishes Positive Phase 3 Data on eDSP for Ataxia-Telangiectasia, Highlighting Sustained Drug Release and Favorable Safety Profile. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quince Therapeutics Inc. published the original content used to generate this news brief via Business Wire  on September 25, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250925:nNDLyJJ11:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNCX","BK4139"],"gpt_icon":0},{"id":"2566591956","title":"Quince Therapeutics Announces Pivotal Phase 3 NEAT Trial for Ataxia-Telangiectasia with Topline Results Expected in Q1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2566591956","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566591956?lang=en_us&edition=fundamental","pubTime":"2025-09-12 04:05","pubTimestamp":1757621136,"startTime":"0","endTime":"0","summary":"Quince Therapeutics Inc., a biotechnology company focused on treating rare diseases, has announced it will host a virtual Investor Day on October 2, 2025. The event will include presentations on the company's Autologous Intracellular Drug Encapsulation  technology and its potential applications in treating rare diseases. A key highlight will be the discussion on the proprietary eDSP System, a drug/device combination designed for chronic corticosteroid administration without toxicity. The company will provide insights into its lead indication, Ataxia-Telangiectasia (A-T), and the ongoing pivotal Phase 3 NEAT clinical trial, with topline results anticipated in the first quarter of 2026. The event will also cover Quince's regulatory strategies and commercial development plans, including its collaboration with Option Care Health. Results from the NEAT study have not yet been presented, as they are expected in 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250911:nNDL7RWpN1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","LU2065731478.USD","QNCX","OPCH","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.quincetx.com","stockEarnings":[{"period":"1week","weight":-0.1324},{"period":"1month","weight":-0.1585},{"period":"3month","weight":0.75},{"period":"6month","weight":0.6649},{"period":"1year","weight":0.931},{"period":"ytd","weight":-0.0806}],"compareEarnings":[{"period":"1week","weight":-0.0035},{"period":"1month","weight":-0.0017},{"period":"3month","weight":0.0177},{"period":"6month","weight":0.0818},{"period":"1year","weight":0.1303},{"period":"ytd","weight":0.0107}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Quince Therapeutics, Inc., a preclinical stage biopharmaceutical company, develops precision therapeutics for debilitating and rare diseases. Its lead compound is NOV004, a systemically administered bone anabolic peptide engineered to target and concentrate at bone fracture sites. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":0.032773},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.075156},{"month":3,"riseRate":0.5,"avgChangeRate":0.133761},{"month":4,"riseRate":0.5,"avgChangeRate":-0.084014},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.087389},{"month":6,"riseRate":0.714286,"avgChangeRate":0.184618},{"month":7,"riseRate":0.285714,"avgChangeRate":-0.077216},{"month":8,"riseRate":0.428571,"avgChangeRate":0.032954},{"month":9,"riseRate":0.571429,"avgChangeRate":0.013938},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.049658},{"month":11,"riseRate":0.571429,"avgChangeRate":0.199459},{"month":12,"riseRate":0.285714,"avgChangeRate":0.079276}],"exchange":"NASDAQ","name":"Quince Therapeutics, Inc.","nameEN":"Quince Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Quince Therapeutics, Inc.(QNCX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Quince Therapeutics, Inc.(QNCX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Quince Therapeutics, Inc.,QNCX,Quince Therapeutics, Inc.股票,Quince Therapeutics, Inc.股票老虎,Quince Therapeutics, Inc.股票老虎国际,Quince Therapeutics, Inc.行情,Quince Therapeutics, Inc.股票行情,Quince Therapeutics, Inc.股价,Quince Therapeutics, Inc.股市,Quince Therapeutics, Inc.股票价格,Quince Therapeutics, Inc.股票交易,Quince Therapeutics, Inc.股票购买,Quince Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Quince Therapeutics, Inc.(QNCX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Quince Therapeutics, Inc.(QNCX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction